logo
logo
COR stock ticker logo

Cencora, Inc.

NYSE•COR
CEO: Mr. Steven H. Collis
セクター: Healthcare
業種: Medical - Distribution
上場日: 1995-04-04
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
連絡先情報
1 West First Avenue, Conshohocken, PA, 19428-1800, United States
610-727-7000
www.cencora.com
時価総額
$62.08B
PER (TTM)
38.1
30.4
配当利回り
0.7%
52週高値
$377.54
52週安値
$271.00
52週レンジ
45%
順位13Top 2.2%
6.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q1 2026 データ

売上高

$85.93B+0.00%
直近4四半期の推移

EPS

$2.88+0.00%
直近4四半期の推移

フリーCF

-$2.42B+0.00%
直近4四半期の推移

2026 Q1 決算ハイライト

主なハイライト

Revenue Growth Strong Revenue reached $85.93 B USD for the quarter, marking a solid 5.5% increase over the prior year period.
Gross Profit Surges Gross profit surged to $3.07 B USD, showing a strong 20.1% increase driven by recent acquisitions.
Net Income Improvement Net income attributable to Cencora grew to $559.65 M USD, improving significantly from $488.60 M USD last year.
Operating Cash Usage Down Cash used in operating activities decreased by $0.4 B USD, totaling $2.31 B USD utilized this quarter.

リスク要因

Opioid Litigation Liability Accrued litigation liability for opioid settlements stands at $4.3 B USD, payable across the next thirteen years.
Asset Impairment Recorded Management recorded a $165.7 M USD goodwill impairment charge related to the U.S. Consulting Services business sale.
Interest Expense Spikes Net interest expense increased substantially by 159.2% due to significant new debt issuance for acquisitions.
Geopolitical Uncertainties Remain Exposure remains high regarding geopolitical uncertainties, macroeconomic shifts, and potential supply chain disruptions globally.

見通し

OneOncology Acquisition Closed The company finalized the majority acquisition of OneOncology for approximately $4.6 B USD cash in February 2026.
New Segment Reporting A new business reporting structure aligning with growth priorities was implemented starting in the first quarter of fiscal 2026.
Credit Facility Expanded The Multi-Currency Revolving Credit Facility was amended, increasing total commitments available up to $5.5 B USD.
Quarterly Dividend Raised Anticipating continued capital needs, the Board increased the quarterly common stock dividend by 9% to $0.60 USD.

同業比較

売上高 (TTM)

MCK stock ticker logoMCK
$397.96B
+15.5%
COR stock ticker logoCOR
$325.78B
+7.4%
CAH stock ticker logoCAH
$244.49B
+10.1%

粗利益率 (最新四半期)

ARGX stock ticker logoARGX
89.3%
-53.8pp
REGN stock ticker logoREGN
85.0%
+3.3pp
EW stock ticker logoEW
78.3%
-2.7pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
MCK$106.71B24.5-245.3%10.2%
REGN$77.56B17.114.8%6.7%
COR$62.08B38.1101.4%10.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.4%
緩やかな成長
4四半期純利益CAGR
-8.0%
収益性の低下
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年5月5日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし